A Case with Familial Mediterranean Fever which Responds Well to Adalimumab Treatment

The role of adalimumab in the treatment of colchicine-resistant familial mediterranean fever: a case report

“…Literature review yielded only five reported cases for the use of adalimumab in FMF patients [16,17,19]. Our case shares many of the characteristics with those cases including the age, the presence of peripheral arthropathy, the genetic mutation, the colchicine resistance, and the marked improvement upon the initiation of adalimumab.…”

“…The most commonly used agent is etanercept followed by infliximab. In all these cases, a favorable response with complete resolution of the clinical manifestations as well as normalization of the acute phase reactants was recorded [14][15][16][17][18][19][20].…”

“…Thus, their exact role has not yet been well clarified [29,30]. Despite these controversies, the efficacy and safety of anti-TNF alpha agents in the treatment of resistant FMF patients in different case reports and case series is an evidence of a potential major role of TNF-alpha in FMF pathogenesis [14][15][16][17][18][19][20].…”

“…Biologic agents have shown significant impact on symptoms improvement as well as a positive effect on the quality of life. In addition, they appear to play a role in amyloidosis prevention [14][15][16][17][18][19][20]. We hereby present a patient who had severe manifestations of FMF and arthritis despite treatment with antiinflammatory agents and colchicine, but showed a dramatically positive response upon administration of adalimumab.…”

“…Data derived from the efficacy of biologics in treatment of various rheumatological diseases had encouraged clinicians to use them in resistant FMF cases [14][15][16][17][18][19][20]31]. There are several case reports to date that use anti-TNF agents in the treatment of FMF.…”